References
PDR Generics. 4th ed. Montvale NJ: Medical Economics, 1998: 146–52
ABPI compendium of data sheets and summaries of product characteristics 1998–99. London: Datapharma Publications Ltd, 1998: 1179–81
Rotmensch HH, Liron M, Tupilski M, et al. Possible association of pneumonitis with amiodarone therapy. Am Heart J 1980 Sep; 100(3): 412–3
Martin II WJ, Rosenow III EC. Amiodarone pulmonary toxicity: recognition and pathogenesis. Part I. Chest 1988; 93: 1067–75
Jessurun GAJ, Boersma WG, Crijns HJGM. Amiodarone-induced pulmonary toxicity: predisposing factors, clinical symptoms and treatment. Drug Saf 1998 May; 18(5): 339–44
Van Mieghem W, Coolen L, Malysse I, et al. Amiodarone and the development of ARDS after lung surgery. Chest 1994; 105: 1642–5
Rotmensch HH, Belhassen B, Swanson B, et al. Steady-state serum amiodarone concentrations: relationship with anti-arrhythmic efficacy and toxicity. Ann Intern Med 1984; 101: 462–9
Mason JW. Toxicity of amiodarone. Circulation 1985; 72 Suppl. 3: 272
Pollak PT, Sharma AD, Carruthers SG. Relation of amiodarone hepatic and pulmonary toxicity to serum drug concentrations and superoxide dismutase activity. Am J Cardiol 1990; 65: 1185–91
Rights and permissions
About this article
Cite this article
Careful monitoring required to minimise the damage of amiodarone-induced pulmonary toxicity. Drugs Ther. Perspect 12, 14–16 (1998). https://doi.org/10.2165/00042310-199812120-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-199812120-00005